Eton Pharmaceuticals, Inc.

For the period ended Dec 31, 2024. Filed Mar 18, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 18, 2025

ETON$64.35+14.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Deficit	Equity
Balances at December 31, 2021	24,626,004	$25	$111,718	$(94,113)	$17,630
.
Stock-based compensation	—	—	4,218	—	4,218
Stock option exercises	25,000	—	35	—	35
Employee stock purchase plan	69,884	—	171	—	171
Common stock issued related to restricted stock units	—	—	—	—	—
Stock warrant exercises	632,231	—	45	—	45
Net loss	—	—	—	(9,021)	(9,021)
Balances at December 31, 2022	25,353,119	25	116,187	(103,134)	$13,078
Stock-based compensation	—	—	3,137	—	3,137
Stock option exercises and vesting of restricted stock units	299,028	1	148	—	149
Employee stock purchase plan	86,782	—	229	—	229
Shares withheld related to net share settlement of stock option exercises	(50,867)	—	(180)	—	(180)
Net loss	—	—	—	(936)	(936)
Balances at December 31, 2023	25,688,062	26	119,521	(104,070)	$15,477
Common stock issued in private placement offering	583,334	1	6,999	—	7,000
Stock-based compensation	—	—	3,165	—	3,165
Employee stock purchase plan	80,933	0	248	—	248
Stock option exercises and vesting of restricted stock units	356,755	0	1,191	—	1,191
Relative fair value of warrants issued in connection with debt	—	—	1,170	—	1,170
Net loss	—	—	—	(3,823)	(3,823)
Balances at December 31, 2024	26,709,084	$27	$132,294	$(107,893)	$24,428

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.